Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 3,101–3,200 of 3,704
Atger, F., Durand, M., Croyal, M., Chavanne, A., Questel, E. L., Foucher, Y., Besnard, C., Nemazanyy, I., Lay, S. L., Prieur, X., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.18.719366
Annemans, L., Johansson, E., Spaepen, E., van Hest, N., Grist, J., Zimner‐Rapuch, S., & Wilding, J. P. H. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646079 · Cited by 1
Anesto, J. B., Dotres, K., & Nicolau, J. (2026) · Nutrición Hospitalaria · doi:10.20960/nh.06592 · Cited by 2
Mortada, I., Quach, V., Lee, A. W., Long, N., Ebel, G., Al‐Abdouh, A., Albayyaa, M., Love, A. N., Mansour, S., Chatila, K., et al. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2026.105384
Noninsulin Medications for Type 2 Diabetes
CASTRO-REVOREDO, I. A., & WEBSTER, S. C. M. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.12.006
Investigating fasting for metabolic health and longevity
Steinhauser, M. L., & Fazeli, P. K. (2026) · Biogerontology · doi:10.1007/s10522-026-10438-9
Pharmacotherapy (Obesity Management Medications)
Blacklock, R. M., Lim, A. Y. L., Koh, H., Miras, A. D., & Brown, A. C. (2026) · Wiley eBooks · doi:10.1002/9781394206148.mdp0070
Alasnag, M. A., Sambola, A., Uchmanowicz, I., Kałużna, M., Sabouret, P. F., Serrano, L., Paradies, V., Parapid, B. J., Banerjee, S., Bachelot, A., et al. (2026) · European Heart Journal Open · doi:10.1093/ehjopen/oeag055
Agboola, F. O., Fahim, S. M., Lin, G. A., Lee, W., Richardson, M., & Rind, D. M. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.5.631 · Cited by 3
Bariatric Surgery in the GLP-1 Era: Decline or Enhanced Acceptance as the Gold Standard?
Goel, R. (2025) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_6_26
Peng, T., Liang, W., Wei, J., Ding, N., Tang, X., & Zhang, Z. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s590529
Donoso, P. D. R. Q., Briones, R. F. Z., Castro, C. P. M., Narváez, D. L. B., Velasco, S. A., & Jimenez, S. N. C. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20261347
Strategie di remissione del prediabete
Vazzana, A., Giannatiempo, V., Cubitosi, V., & Dei, A. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01802-5
Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial
Heerspink, H. J. L., Soler, M. J., Beernink, J. M., Jongs, N., Guldris, S. C., Cruzado, J. M., Puchades, M. J., López-Martínez, M., Apperloo, E. M., Waanders, F., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001051 · Cited by 3
Rivera, R., Castaneda, R., Sobel, T., & Andrade, M. D. H. (2026) · Springer eBooks · doi:10.1007/978-3-032-18203-6_8 · Cited by 3
Diabetes and Obesity as Catalysts in MASH Progression: Mechanisms and Emerging Therapies
Munda, B., Bhutia, C., Deepti, & Khatri, M. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.011
The pen vs the scalpel: how weight loss drugs are changing the face of medicine
Ahmed, A., & Patel, P. (2026) · Bulletin of The Royal College of Surgeons of England · doi:10.1308/rcsbull.2026.58
AlRashidi, A. M., & Alhowail, A. H. (2026) · International Journal of Pharmacology · doi:10.31083/ijp49432
Short-term effect of tirzepatide on serum calcitonin in adults with obesity
Angelopoulos, N., Simeakis, G., Androulakis, I., Rizoulis, A. A., Boniakos, A., Mentzelopoulou, P., Korakovouni, A., Zianni, D., Petkova, V., Livadas, S., et al. (2026) · Endocrine · doi:10.1007/s12020-026-04655-y · Cited by 1
Davies, M., & Härmark, L. (2026) · Drug Safety · doi:10.1007/s40264-026-01676-4
Mitochondrial remodeling as a effector of glp-1 therapy in obesity and diabetes: review
Alhindi, Y. Z. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/bfye5lnqza
Finding Common Ground: Updates from ObesityWeek 2025
Millard, A. J. (2026) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2026.04.005
Robinson, R., Sarkar, T. D., Moore, S., & Malhotra, A. (2026) · Current Sleep Medicine Reports · doi:10.1007/s40675-026-00373-z
Sattar, N. A., Tchang, B. G., Vincent, R. P., Wang, H., Murphy, M., Dunn, J. P., Dimitriadis, G. K., & Brumm, J. F. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02883-7 · Cited by 1
Fredrick, T. W., Maselli, D., Vargas, E., Wooley, C., Gala, K. S., Añazco, D., Ciotlos, S., O’Connor, T., Dayyeh, B. K. A., McGowan, C., et al. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08642-0
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Perera, K., BAKER, J., Smallman, K., Pickering, K., Harry, P., Anderson, D., Orr‐Walker, B., Babor, R., & Simmons, D. S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113296 · Cited by 1
Integrating lifespan biology into obesity science
Suliman, S. G. I., & Sargent, J. L. (2026) · Metabologia · doi:10.1007/s44357-026-00005-7
The effect of GLP-1RAs and co-agonists on body composition across obesity and type 2 diabetes
Sun, L. L., Liu, H. F., Zhang, X., Zuo, F., Kong, Y., Feng, J., & Nian, X. (2026) · European journal of medical research · doi:10.1186/s40001-026-04534-2
McCormick, N. P., de Moura, C. S., Zhang, J., Holladay, E. E., Xie, F., Mehta, T. S., Baker, J. F., & Curtis, J. R. (2026) · ACR Open Rheumatology · doi:10.1002/acr2.90068
Kumaran., R., & Mohan., A. (2026) · International Conference on Recent Advances in Electrical, Electronics, Ubiquitous Communication, and Computational Intelligence (RAEEUCCI) · doi:10.1109/raeeucci67649.2026.11504461
Sexual dysfunction in patients with Type 2 diabetes: A South Asian perspective
Selim, S. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102108
Metabolic biomarkers predict subclinical cardiac remodeling in obese individuals
Hu, M., Wang, H., Mei, Z., Gong, C., Lan, L., Ma, Z., Zhang, B., Fan, H., Zhang, Y., Wang, H., et al. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.183
Digital Augmentation of Glucagon-Like Peptide-1 for Obesity Management: Retrospective Study
Davey, B., Dabash, O., Khanna, R., Cornell, P. Y., & Huckvale, K. (2026) · Journal of Medical Internet Research · doi:10.2196/100728
Pillai, A. A., Godin, S., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001310 · Cited by 1
Masuzaki, H., Nagashima, H., Shingaki, T., Oura, T., & Tatsuno, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70850
Khan, S., & Stansbury, R. C. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag119
Moyal, J., & Rehany, B. (2026) · University of Toronto Medical Journal · doi:10.33137/utmj.v103i2.46711
Challenges in mitigating weight regain with incretin-based therapy
Scheen, A. J. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00871-8 · Cited by 1
Kaufman, R. C. (2026) · Research Square · doi:10.21203/rs.3.rs-9657897/v1
The Possible Link Between Tirzepatide and Pulmonary Embolism: A Case Report and a Narrative Review
Arecco, A., Cocchiara, F., & Maggi, D. C. (2026) · Endocrines · doi:10.3390/endocrines7020020
Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications
Lewis, K. H., Zhang, F., LeCates, R. F., Argetsinger, S., Albert, S., Iyer, G. S., Connolly, J. G., Wharam, J. F., Arterburn, D. E., Ross‐Degnan, D., et al. (2026) · Obesity · doi:10.1002/oby.70208
Emerging Cardiorenal Protective Therapies in Lupus Nephritis
Capón, I. M., Sandino, J., Galindo, M., & Morales, E. (2026) · Drugs · doi:10.1007/s40265-026-02337-7 · Cited by 2
Zadeh, A. T., Chiapparelli, E. A., Amoroso, K., Guven, A. E., Zhu, J., Köhli, P., Verna, B., Mielke, A. M., Shue, J., Burkhard, M. D., et al. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261446300 · Cited by 2
Impact of Pharmacist Involvement in Health Literacy for Patients With Obesity
Mancuso, S., Axtell, S., Nixon, B., & Tasseff, N. (2026) · Journal of Pharmacy Practice · doi:10.1177/08971900261450448 · Cited by 2
Abedi, M. M., Alabid, I., Alghoul, W. I. I., Salama, R. A. A., Lami, K. A. H. A., Marzougui, H., Swalha, B. R. R., Shaikh, S. A., Khan, S. S., & Mohamed, N. A. E. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103767
Lopes, F. R., Johnson, T. R., Ferreira, F. S., Lopes, A. A., Amorim, M. A., Lima, T. G. D. M. N., MARTINS, G. A. B., Melo, N. F., Araujo, Q. D., Dario, M. B. A., et al. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n60-028
Wu, J., Lin, Y.-M., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M., & Lai, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1769425
Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 1 Diabetes
Buros‐Stein, A., PAULEY, M. E., & Snell‐Bergeon, J. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.003
Alam, A. (2026) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_17_26
MAKHMUTOV, A., & Qureshi, F. M. (2026) · Cureus · doi:10.7759/cureus.108868
AVALIAÇÃO COMPARATIVA DOS EFEITOS ADVERSOS DE TERAPIAS INJETÁVEIS PARA CONTROLE DO PESO CORPORAL
Sousa, M. E. D. D., & Caetano, R. C. D. P. E. S. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n60-033
Łupina, K., Dziewierz, A., Janczura, J., & Siudak, Z. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02709-1 · Cited by 1
Depression Associated with Other Medical Conditions
Sunzeri, F., & Sunzeri, E. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_12
Implications of GLP-1 RA Therapy on Skeletal Health and Orthopedics: A Commentary
Gertzulin, M., & Drake, M. T. (2026) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1177/15563316261450988
Estler, B., Fröhlich, H., Täger, T., Heins, J., Frey, N., & Frankenstein, L. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134560
Wallentowitz, L., García, M. G., Atorrasagasti, C., Harms, C., Huhn, E. A., Roser, P., Verlohren, S., Giesen, E. M., & Blois, S. M. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10053-6 · Cited by 4
Suarez, S. I., Bilori, B., Aluri, S. V., & Das, S. (2026) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2025.1308
Novel tirzepatide: A torchbearer in type 2 diabetes mellitus and obesity
Musaliyar, A., Kumar, N., Terrance, S., Reni, A. R., & Ashwini Aithal, P. (2026) · Journal of Medical Society · doi:10.4103/jms.jms_28_25
Elawa, Z., Khalil, A., Kardousha, A., Elawwa, A., & Soliman, A. T. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113332
Weight Management in Menopause
Lu, V., Tayachew, B., Chevtsov, A., & Nicklas, J. M. (2026) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2026.04.002
Chaparala, P., Rongali, D. A., Khot, M., Rangachari, B., Ahmed, K. U., Suri, S., Greeshma, M., & Shafiq, M. M. (2026) · Cureus · doi:10.7759/cureus.109350
ICER report demonstrates both the value and challenges in financing of weight loss medications
Ramachandran, S., Urick, B., & Thomas, T. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.6.753
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
Davies, I., Holst, J. J., ROSENKILDE, M. M., & Tan, T. (2026) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-061824-043740 · Cited by 3
Benedict, B. C., White-Gilliam, D., Pradhan, A., Yakdan, S. M., Hammo, A., Budd, L., Arkam, F., Tang, S. Y., Schechtman, K. B., Cheng, A. L., et al. (2026) · medRxiv · doi:10.64898/2026.05.20.26353666
The role of bariatric metabolic endoscopy in 2026 and beyond
Norton, B. C., Ranganath, S., Bhandari, M., & Haidry, R. J. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103561
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9783878/v1
Troshina, E. A., Antsiferov, M. B., As, A., Bakulin, I. G., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2026) · Problems of Endocrinology · doi:10.14341/probl13784 · Cited by 2
Mihălțan, F.-D., Borcea, C.-I., & Constantin, A. A. (2026) · Life · doi:10.3390/life16050802
Peary, A., Vaidya, N., Jakicic, J., & Chao, A. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01426-y · Cited by 1
SEMAGLUTIDE FOR WEIGHT REDUCTION: A COMPARATIVE ANALYSIS WITH OTHER PHARMACOLOGICAL TREATMENTS
Handzel, M., Czerniewska, J., Jurkowska, K., Madrzak, J., Endler, O., Dybicz, M., Ciastoń, M., Filuk, M., Fidelus, J., & Dutkiewicz, D. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5726
Tucker, S. L., & Humadi, S. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08741-y
McGuane, C., Farhadhar, N., Sharieff, K. A., Petrosky, S. N., & Alabasi, K. (2026) · Cureus · doi:10.7759/cureus.109731 · Cited by 1
Choi, H., & Hwang, A. Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70903
Highlighting the latest research: May 2026
McSharry, S., Binu, R., & Lotto, R. R. (2026) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2026.0029
Laique, S. N., Bansal, P., Nadeem, M. A., Wehrle, C. J., Verma, S., Giuseppucci, A., Berber, B., Sanha, V., Hellickson, K., Maura, G., et al. (2026) · Liver Transplantation · doi:10.1097/lvt.0000000000000911 · Cited by 1
Alnagar, A., Khan, M. U., Ahmad, M. S., Mersal, M., Ayyad, M., Hassan, R., & Noormohamed, M. S. (2026) · World Journal of Transplantation · doi:10.5500/wjt.v16.i2.118702
Le, D., Kilpatrick, M., Kraft, W. K., Grams, M. E., Jaar, B. G., & Shin, J.-I. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106618
GLP-1 and Nutrient Stimulated Hormone Targets: Beyond Weight Loss
Ryan, D. H. (2026) · Dermatologic Surgery · doi:10.1097/dss.0000000000005113
de Velasco, L. M. C., Flores, J. G., Fischer, G. K., de la Vega, M., Morales-Arteaga, J. L., Margalef, A. B., Mora, S. S., Abruch-Fleisher, A., & Cervera, A. A. (2026) · Cureus · doi:10.7759/cureus.109931
Zhang, L., Hu, J., Huang, C., Gao, X., Pang, D., & Duan, L. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102390
TIRZEPATIDA E OS RISCOS DO USO SEM PRESCRIÇÃO MÉDICA
Silva, B. E., Alves, N. D., Francelino, J. D. S., Spaziani, A. O., Eleutério, B. M. G., da Silva, F. S., Gonzaga, D. M. I. D. S., & Franco, R. F. (2026) · Revista de Geopolítica · doi:10.56238/revgeov17n6-005 · Cited by 1
Hornick, M. A., Duffy, A. J., Floch, N. R., & Morton, J. M. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02120-4
Elatrebi, S. F., Abuyadek, R. M., Abdelbar, S. M. M., Ahmad, M. S., Ayyad, M., Quoritem, M. A., Majid, R. O. A., Arafat, M., Amgad, A., & Alnagar, A. (2026) · World Journal of Transplantation · doi:10.5500/wjt.120572
Akinrinmade, A. O., Sakariya, D., Yousef, M., et al. (2026) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2025.1284
Салухов, В. В., Arutyunov, G. P., Vasilyeva, I. A., Cherkashin, D. V., Prochik, Y. E., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-136
Салухов, В. В., Galstyan, G. R., Неймарк, А. Е., Samoilov, V. S., Khalimov, Y. S., Karonova, T. L., & Sukhotskaia, N. A. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-155
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome
Liao, X. C., Huang, T., Hong, D. S., & Luo, L. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag152
Tirzepatide in type 1 diabetes: beyond mere weight loss
Panou, T., Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2685653
Hypogonadism and Metabolic Disorders
Cignarelli, A., Genchi, V. A., & Jayasena, C. N. (2026) · Endocrinology · doi:10.1007/978-3-319-29456-8_50-1 · Cited by 1
Jefferson Lifestyle Program: Protocol for an Implementation Study (Preprint)
Cunningham, A., Hass, R. W., Leahy, C., Baumgarten, J., Kyrillos, J. V., Pinkham, C., Smith, M., Marine, V., Mohan, S., & Flattau, A. (2026) · JMIR Research Protocols · doi:10.2196/103495
Skvortsov, V. V., Skvortsova, E. M., & Makhnach, D. A. (2026) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2605-04
Corrêa, L. M. D. A., Brandão, L., Silva, Y. R. D., Fernandes, C. C. S., Fossati, G. W., Queiroz, L. R. G. D. M., Zanella, J., & Hernandes, F. G. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101037
Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans
Dall, T. M., Chen, F., Sapra, T., Ferguson, C., Hafida, S., Livingston, T., Moody, A., ElSayed, N. A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0006 · Cited by 1
The Cost of Inaction in Treating Obesity in the U.S.
Sapra, T., Chen, F., Dall, T. M., Hafida, S., Moody, A., Ferguson, C., Livingston, T., ElSayed, N. A., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0011
Clinical and economic aspects of semaglutide use in the treatment of obesity
Tibilova, A. L., Kozaeva, D. D., Aslakhanova, R. R., Tedety, V. Z., Tazurkaeva, M. Z., Gurtsieva, D. E., Kanteeva, E. E., Gabueva, M. S., Guatsaeva, V. I., Dzhigkaeva, A. M., et al. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.369
Neue Medikamente zur Gewichtsreduktion – ethische Herausforderungen
Weidinger, I. S. (2026) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2840-0244
ESTRATEGIAS FARMACOLÓGICAS PARA EL MANEJO DE ENFERMEDADES CRÓNICAS: EVIDENCIA ACTUAL Y DESAFÍOS
Riofrio, A. A. O., Fiallo, M. A. C., Herrera, A. R., et al. (2026) · VitalyScience Revista Científica Multidisciplinaria · doi:10.56519/1b418y72
Kunicki, M., Katulska, Z., Wolert, W., & Kunicka, A. (2026) · Maturitas · doi:10.1016/j.maturitas.2026.109025
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.